Challenge
At registration and beyond, regulatory risk is at its highest, as approval depends on anticipating regulatory concerns, defending your evidence package, and responding effectively to scrutiny that can delay, restrict, or derail approval and commercial launch. After approval, maintaining compliance, managing safety, and keeping pace with evolving requirements become critical. Without clear ownership and the right experience, approval status and asset value can quickly be put at risk. Lifecycle strategy is also vital to create value.
How we can help you
- Marketing Application preparation and defence, and label optimisation
- Post-approval compliance and safety oversight
- Lifecycle strategy and plans, and Fractional Leadership to deliver
Securing approval under regulatory scrutiny
As your programme moves toward marketing authorisation (MA), pressure intensifies to prepare, submit, and defend your application under close regulatory scrutiny. Any gaps in readiness or cross-functional coordination can delay submission, trigger extensive questions from regulators, or limit scope of approval – putting timelines, reputation, and asset value at risk.
tranScrip Solution
tranScrip gives you senior-led expertise in MA strategy and delivery across the European Medicines Agency (EMA), the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), the US Food and Drug Administration (FDA), and other global authorities. We help you define regulatory submission pathways that are aligned to commercial objectives, manage complex multi-region applications, and integrate clinical, nonclinical, and Chemistry, Manufacturing and Controls (CMC) data into a coherent, regulator-ready dossier. During regulatory review, we help you coordinate strong responses to regulators and defend key issues strategically – protecting timelines and optimising labelling for long-term commercial success.
What tranScrip provides
- MA submission strategy and planning
- Coordination and management of global regulatory submissions including MHRA, EMA, and FDA (New Drug Application [NDA]/Marketing Authorisation Application [MAA]/Biologics License Application [BLA]
- Integration of clinical, nonclinical, CMC, and regulatory components
- Preparation for regulatory meetings and submission milestones
- Lead authorship and critical review of submission documents
- Regulatory question management and responses during review
- Strategic support for objections, major questions, and appeals
- Senior regulatory, medical and nonclinical leadership through “preparation to approval” process
Proven Success
EU Regulatory Strategy and MAA Conversion for a Complex Topical Product
tranScrip supported a US-approved complex topical product in preparation for EU market entry, defining the regulatory strategy, converting a 505(b)(2) NDA dossier into an EU-ready MAA, coordinating Scientific Advice across three countries, and managing the DCP with temporary MAH support to enable submission progress.
Staying in control after approval
After approval, growing complexity across safety requirements, post-approval commitments, and ongoing regulatory obligations can strain your team and fragment oversight. The decisions you make at this stage shape not only compliance, but also market access, lifecycle strategy, and long-term product value – creating real risk of misalignment and lost opportunity if not actively managed.
tranScrip Solution
tranScrip gives you senior-led regulatory and safety support to help you maintain robust post-approval compliance across the product lifecycle. We help you manage regulatory variations, renewals, label updates, and regulatory commitments, while adapting strategy to evolving data and market needs. Through post-approval study support, pharmacovigilance expertise, and benefit–risk assessment, we help you make clear, defensible decisions and maintain compliance, regulator confidence, and long-term commercial viability.
What tranScrip provides
- Ongoing regulatory compliance and maintenance activities
- Design and oversight of post-approval programme commitments
- Pharmacovigilance and safety oversight for marketed products
- Signal evaluation and benefit–risk assessment support, as marketed data evolve
- Senior regulatory and safety leadership to maintain compliance
- Cross-functional coordination across regulatory, medical and safety
Proven Success
PV Vendor Oversight and Health Authority Response Management
tranScrip supported a large biopharma company in responding to multiple urgent FDA NISS safety requests, providing expert PV oversight, reviewing vendor case identification and classification methods, correcting flawed adverse event severity and duplicate case methodology, and delivering high-quality authority responses that protected label strategy.
Creating and protecting long-term value beyond approval
At the product registration and approval stage, focus is rightly on success in the initial launch indication, but to build value a clear view of lifecycle strategy is equally important . Biopharma can frequently lack the bandwidth to consider both, potentially undermining value for both the asset and the company.
tranScrip Solution
tranScrip gives you senior-led expertise to build an integrated lifecycle strategy aligned across medical, regulatory and commercial disciplines in parallel with securing first approval and launch. Additionally, through disciplined post-approval regulatory and safety leadership, we help you maintain compliance in your initial launch indication, manage ongoing commitments, and adapt strategy to evolving evidence — protecting regulatory confidence and long-term commercial success.
What tranScrip provides
- Fractional medical, clinical, regulatory and commercial leadership
- Support for market access submissions and stakeholder engagement
- Lifecycle management strategy to extend and protect value
- Medical and commercial strategy input linked to label evolution
- Partnering support informed by regulatory and market access strategy
Proven Success
NDA, MAA and Launch Support for a Systemic Antifungal Programme
tranScrip provided specialist clinical oversight for a systemic fungal disease programme, supporting confirmatory trials, delivery of the NDA and MAA, and launch readiness activities including training for sales, pharmacovigilance and medical affairs teams across Europe, helping enable global rollout and expansion to a second licensee.
